# Cardiff Oncology (CRDF) — Earnings

CRDF · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/crdf/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | Sep 30, 2025 |
| EPS actual | −$0.17 |
| EPS estimate | −$0.21 |
| EPS surprise | +17.07% |
| Revenue surprise | −4.00% |
| Revenue | $120,000.00 |
| Revenue estimate | $125,000.00 |
| Reported | Nov 6, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1213037/000119312525269424/crdf-20250930.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Nov 6, 2025 | −$0.21 | −$0.17 | 17.07% | $125,000.00 | $120,000.00 |
| Q2 2025 | Jul 29, 2025 | −$0.19 | −$0.21 | -9.09% | $109,375.00 | $121,000.00 |
| Q1 2025 | May 8, 2025 | −$0.19 | −$0.20 | -8.05% | $92,857.00 | $109,000.00 |
| Q4 2024 | Feb 27, 2025 | −$0.25 | −$0.22 | 10.71% | $100,000.00 | $153,000.00 |
| Q3 2024 | Nov 7, 2024 | −$0.27 | −$0.25 | 7.24% | $70,000.00 | $165,000.00 |
| Q2 2024 | Aug 8, 2024 | −$0.25 | −$0.26 | -5.05% | $58,750.00 | $163,000.00 |
| Q1 2024 | May 2, 2024 | −$0.25 | −$0.22 | 11.47% | $62,500.00 | $205,000.00 |
| Q4 2023 | Feb 29, 2024 | −$0.27 | −$0.21 | 21.38% | $50,000.00 | $156,000.00 |
| Q3 2023 | Nov 2, 2023 | −$0.28 | −$0.22 | 22.54% | $50,000.00 | $141,000.00 |
| Q2 2023 | Aug 9, 2023 | −$0.26 | −$0.25 | 4.14% | $50,000.00 | $108,000.00 |
| Q1 2023 | May 4, 2023 | −$0.23 | −$0.25 | -10.62% | $65,600.00 | $83,000.00 |
| Q4 2022 | Mar 2, 2023 | −$0.24 | −$0.20 | 14.89% | $73,250.00 | $100,000.00 |
| Q3 2022 | Nov 3, 2022 | −$0.26 | −$0.20 | 24.24% | $68,200.00 | $93,000.00 |
| Q2 2022 | Aug 4, 2022 | −$0.25 | −$0.24 | 2.44% | $93,000.00 | $91,000.00 |
| Q1 2022 | May 5, 2022 | −$0.23 | −$0.25 | -7.16% | $56,600.00 | $74,000.00 |
| Q4 2021 | Feb 24, 2022 | −$0.17 | −$0.23 | -33.95% | $41,000.00 | $133,000.00 |
| Q3 2021 | Nov 4, 2021 | −$0.17 | −$0.17 | 0.00% | $40,000.00 | $86,000.00 |
| Q2 2021 | Aug 5, 2021 | −$0.15 | −$0.17 | -13.33% | $152,500.00 | $68,000.00 |
| Q1 2021 | May 6, 2021 | −$0.15 | −$0.14 | 5.08% | $152,500.00 | $72,000.00 |
| Q4 2020 | Feb 25, 2021 | −$0.14 | −$0.19 | -35.71% | $43,333.00 | $119,000.00 |

## Frequently Asked Questions

### When did Cardiff Oncology (CRDF) last report earnings?

Cardiff Oncology last reported on Nov 6, 2025, covering fiscal Q3 2025.

### Did CRDF beat earnings estimates?

Yes. Cardiff Oncology reported EPS of −$0.17 for Q3 2025 against a −$0.21 estimate — a 17.07% beat.

### How much revenue did CRDF report last quarter?

Cardiff Oncology reported $120,000.00 in revenue for Q3 2025, against a consensus estimate of $125,000.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).